A recap of the top videos and podcasts from Contemporary OB/GYN in September 2026, featuring expert interviews on salpingectomy, testosterone evidence, and more.

Fezolinetant was linked to VMS and sleep improvements by week 4 in the real-world OPTION-VMS study, presented at the International Menopause Society World Congress.

Hugh Taylor, MD, outlines a stepwise approach to endometriosis therapy, from first-line oral contraceptives to oral GnRH antagonists for progestin-resistant patients.

On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.

Psychotherapy addresses fear and anxiety that can blunt hormone and pelvic floor therapy in menopause care, according to Sheryl Kingsberg, PhD.

SUID was the largest single contributor to the Black-White infant mortality gap in 2024 and drove the biggest share of its rise since 2020.

Garima Sharma, MD, outlines validated cardiac risk scores for antenatal screening and the postpartum transitions needed to keep high-risk patients from being lost to follow-up.

Anti-CGRP antibody exposure in early pregnancy was linked to higher spontaneous abortion risk; propranolol was not.